Journal of Infection最新文献

{"title":"Disseminated tuberculosis is associated with impaired T cell immunity mediated by non-canonical NF-κB pathway","authors":"","doi":"10.1016/j.jinf.2024.106231","DOIUrl":"10.1016/j.jinf.2024.106231","url":null,"abstract":"<div><h3>Objectives</h3><p>The mechanism that leads to disseminated tuberculosis in HIV-negative patients is still largely unknown. T cell subsets and signaling pathways that were associated with disseminated tuberculosis were investigated.</p></div><div><h3>Methods</h3><p>Single-cell profiling of whole T cells was performed to identify T cell subsets and enriched signaling pathways that were associated with disseminated tuberculosis. Flow cytometric analysis and blocking experiment were used to investigate the findings obtained by transcriptome sequencing.</p></div><div><h3>Results</h3><p>Patients with disseminated tuberculosis had depleted Th1, Tc1 and Tc17 cell subsets, and IFNG was the most down-regulated gene in both CD4 and CD8 T cells. Gene Ontology analysis showed that non-canonical NF-κB signaling pathway, including NFKB2 and RELB genes, was significantly down-regulated and was probably associated with disseminated tuberculosis. Expression of several TNF superfamily ligands and receptors, such as LTA and TNF genes, were suppressed in patients with disseminated tuberculosis. Blocking of TNF-α and soluble LTα showed that TNF-α was involved in IFN-γ production and LTα influenced TNF-α expression in T cells.</p></div><div><h3>Conclusions</h3><p>Impaired T cell IFN-γ response mediated by suppression of TNF and non-canonical NF-κB signaling pathways might be responsible for disseminated tuberculosis.</p></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":null,"pages":null},"PeriodicalIF":14.3,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0163445324001658/pdfft?md5=5d2fbe20fa7715a196b6288b8e496a06&pid=1-s2.0-S0163445324001658-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141735548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Attributable mortality of candidemia – Results from the ECMM Candida III multinational European Observational Cohort Study","authors":"","doi":"10.1016/j.jinf.2024.106229","DOIUrl":"10.1016/j.jinf.2024.106229","url":null,"abstract":"<div><h3>Introduction</h3><p>Despite antifungal advancements, candidaemia still has a high mortality rate of up to 40%. The ECMM <em>Candida</em> III study in Europe investigated the changing epidemiology and outcomes of candidaemia for better understanding and management of these infections.</p></div><div><h3>Methods</h3><p>In this observational cohort study, participating hospitals enrolled the first ten consecutive adults with blood culture-proven candidemia. Collected data included patient demographics, risk factors, hospital stay duration (follow-up of 90 days), diagnostic procedures, causative <em>Candida</em> spp., management details, and outcome. Controls were included in a 1:1 fashion from the same hospitals. The matching process ensured similarity in age (10-year range), primary underlying disease, hospitalization in intensive care versus non-ICU ward, and major surgery within 2 weeks before candidemia between cases and controls. Overall and attributable mortality were described, and a survival probability for cases and controls was performed.</p></div><div><h3>Results</h3><p>One hundred seventy-one pairs consisting of patients with candidemia and matched controls from 28 institutions were included. In those with candidemia, overall mortality was 40.4%. Attributable mortality was 18.1% overall but differed between causative <em>Candida</em> species (7.7% for <em>Candida albicans</em>, 23.7% for <em>Candida glabrata/Nakaseomyces glabratus</em>, 7.7% for <em>Candida parapsilosis</em> and 63.6% for <em>Candida tropicalis</em>). Regarding risk factors, the presence of a central venous catheter, total parenteral nutrition and acute or chronic renal disease were significantly more common in cases versus controls. Duration of hospitalization, and especially that of ICU stay, was significantly longer in candidemia cases (20 (IQR 10–33) vs 15 days (IQR 7–28); p = 0.004).</p></div><div><h3>Conclusions</h3><p>Although overall and attributable mortality in this subgroup analysis of matched case/control pairs remains high, the attributable mortality appears to have decreased in comparison to historical cohorts. This decrease may be driven by improved prognosis of <em>Candida albicans</em> and <em>Candida parapsilosis</em> candidemia; whereas candidemia due to other <em>Candida</em> spp. exhibits a much higher attributable mortality.</p></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":null,"pages":null},"PeriodicalIF":14.3,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0163445324001634/pdfft?md5=3dd60375c20eca28ed11eb006e86db75&pid=1-s2.0-S0163445324001634-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141690856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The safety of antivirals and neutralising monoclonal antibodies used in prehospital treatment of Covid-19","authors":"","doi":"10.1016/j.jinf.2024.106227","DOIUrl":"10.1016/j.jinf.2024.106227","url":null,"abstract":"<div><h3>Objective</h3><p>This proof-of-principle pharmacovigilance study used Electronic Health Record (EHR) data to examine the safety of sotrovimab, paxlovid and molnupiravir in prehospital treatment of Covid-19.</p></div><div><h3>Method</h3><p>With NHS England approval, we conducted an observational cohort study using OpenSAFELY-TPP, a secure software-platform which executes analyses across EHRs for 24 million people in England. High-risk individuals with Covid-19 eligible for prehospital treatment were included. Adverse events (AEs) were categorised into events in the drug’s Summary of Product Characteristics (SmPC), drug-reactions and immune-mediated. Cox models compared risk across treatments. A pre-pandemic record analysis was performed for comparative purposes.</p></div><div><h3>Results</h3><p>Between 2021–2023, 37,449 patients received sotrovimab, paxlovid or molnupiravir whilst 109,647 patients made up an eligible-but-untreated population. The 28-day rates of AEs were low: SmPC 0.34 per 1000 patient-years (95% CI 0.32–0.36); drug-reactions 0.01 (95% CI 0.01–0.02) and immune-mediated 0.03 (95% CI 0.03–0.04), and similar or lower than the pre-pandemic period. Compared with the eligible but untreated population, sotrovimab and paxlovid associated with a risk of SmPC AE [adjHR 1.36 (95% CI 1.15–1.62) and 1.28 (95% CI 1.05–1.55), respectively], whilst sotrovimab associated with a risk of drug-reactions [adjHR 2.95 (95% CI 1.56–5.55)] and immune-mediated events [adjHR 3.22 (95% CI 1.86–5.57)].</p></div><div><h3>Conclusion</h3><p>Sotrovimab, paxlovid and molnupiravir demonstrate acceptable safety profiles. Although the risk of AEs was greatest with sotrovimab, event rates were lower than comparative pre-pandemic period.</p></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":null,"pages":null},"PeriodicalIF":14.3,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0163445324001610/pdfft?md5=5dc616dc8ed4c534e6d44c8ecc91c9d9&pid=1-s2.0-S0163445324001610-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141635569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detection of Bordetella spp. in children with pertussis-like illness from 2018 to 2024 in China","authors":"","doi":"10.1016/j.jinf.2024.106222","DOIUrl":"10.1016/j.jinf.2024.106222","url":null,"abstract":"<div><h3>Objective</h3><p>To evaluate the role of <em>Bordetella pertussis</em> (<em>B. pertussis</em>), <em>B. parapertussis</em>, <em>B. holmesii,</em> and <em>B. bronchiseptica</em> on pertussis resurgence in China, particularly the sharp rise since the latest winter.</p></div><div><h3>Methods</h3><p>Nasopharyngeal swabs collected from children with pertussis-like illness from January 2018 to March 2024 were cultured to detect <em>B. pertussis</em>, <em>B. parapertussis</em>, <em>B. holmesii</em>, and <em>B. bronchiseptica</em>, and tested for all of these except for <em>B. bronchiseptica</em> using a pooled real-time polymerase chain reaction (PCR) kit targeting insertion sequences <em>ptxS1</em>, <em>IS481</em>, <em>IS1001</em>, and <em>hIS1001</em>.</p></div><div><h3>Results</h3><p>Out of the collected 7732 nasopharyngeal swabs, 1531 cases tested positive for <em>B. pertussis</em> (19.8%, 1531/7732), and 10 cases were positive for <em>B. parapertussis</em> (0.1%, 10/7732). <em>B. holmesii</em> and <em>B.bronchiseptica</em> were not detected. The number of specimens and the detection rate of <em>B. pertussis</em> were 1709 and 26.9% (459/1709) in 2018, 1936 and 20.7% (400/1936) in 2019, which sharply declined to 308 and 11.4% (35/308) in 2020, 306 and 4.2% (13/306) in 2021, and then notably increased to 754 and 17.6% (133/754) in 2022, 1842 and 16.0% (295/1842) in 2023, 877 and 22.3% (196/877) in the first quarter of 2024. The proportion of children aged 3 to less than 6 years (preschool age) and 6 to 16 years (school age) in pertussis cases increased significantly during the study period, especially the proportion of school-aged children increased from 2.0% (9/459) in 2018 to 40.8% (80/196) in 2024.</p></div><div><h3>Conclusions</h3><p><em>B. pertussis</em> was the predominant pathogen among children with pertussis-like illness in China, with sporadic detection of <em>B. parapertussis</em> and no detection of <em>B. holmesii</em> or <em>B.bronchiseptica</em>. The preschool and school-age children are increasingly prevalent in <em>B. pertussis</em> infection cases, which may be associated with the latest rapid escalation of pertussis outbreak.</p></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":null,"pages":null},"PeriodicalIF":14.3,"publicationDate":"2024-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0163445324001567/pdfft?md5=0d5f24dc16ce2ab79fadf72e5c166182&pid=1-s2.0-S0163445324001567-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141604444","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of COVID-19 vaccine spring boosters on COVID-19 hospital admissions in England 2022/23","authors":"","doi":"10.1016/j.jinf.2024.106221","DOIUrl":"10.1016/j.jinf.2024.106221","url":null,"abstract":"<div><h3>Background</h3><p>In the spring of 2022 and 2023 COVID-19 vaccine boosters were recommended for those aged ≥75 years in England as well as those in an immunosuppression risk group. The aim was to reduce severe COVID-19 disease in these groups.</p></div><div><h3>Methods</h3><p>The large difference in coverage between those above and below age 75 years was the basis for applying an age-discontinuity approach for measuring the impact of vaccination on COVID-19 hospitalisations in both spring 2022 and 2023. Hospitalisations in individuals positive by PCR for COVID-19 were obtained from the national secondary user service hospital dataset. The ratio of hospital counts by each year of age in 8-week periods after compared to before the roll out was modelled using negative binomial regression to estimate the discontinuity at age 75 years.</p></div><div><h3>Results</h3><p>A clear discontinuity was seen at age 75 years of 17.0% (95% CI: 6.1%−26.6%) in 2022 and 18.0% (3.3%−30.4%) in 2023. If applied to those aged ≥75 years this translates to 1302 and 418 averted hospitalisations in the 8-week period in 2022 and 2023, respectively.</p></div><div><h3>Conclusions</h3><p>This study shows a clear impact of vaccination on preventing COVID-19 hospitalisations and compliments other epidemiological methods assessing the impact of COVID-19 vaccines.</p></div><div><h3>Plain Language Summary</h3><p>One way to see if the booster vaccines doses given to protect against COVID-19 disease are working is to compare hospital admissions in groups of people who were and were not eligible for the dose. In England the spring booster doses were recommended for those aged 75 years and above. We could therefore compare hospitalisations in those above this age to those just below (aged 65–74) and see if there is a step change in rates from age 74 to 75 in the time after the vaccine was given. The results showed hospitalisations were about 18% lower in the group that were eligible, which is evidence that the vaccine is protecting against severe COVID-19.</p></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":null,"pages":null},"PeriodicalIF":14.3,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0163445324001555/pdfft?md5=f732d76f3054e7a9cc676e02dd2a637c&pid=1-s2.0-S0163445324001555-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141602068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness and duration of protection of primary and booster immunisation against meningococcal serogroup C disease with meningococcal conjugate C and ACWY vaccines: Systematic review","authors":"","doi":"10.1016/j.jinf.2024.106228","DOIUrl":"10.1016/j.jinf.2024.106228","url":null,"abstract":"<div><h3>Objectives</h3><p>To estimate vaccine effectiveness (VE) and duration of protection of single primary and booster immunisation with meningococcal C (MenC) and ACWY (MenACWY) conjugate vaccines in preventing MenC invasive meningococcal disease (IMD).</p></div><div><h3>Methods</h3><p>We performed a systematic review on studies of VE and immunogenicity (rSBA/hSBA titers) of participants aged 12–23 months for primary and 6–18 years for booster immunisation (last search: 18 August 2023). Risk of bias and certainty of evidence were evaluated (PROSPERO: CRD42020178773).</p></div><div><h3>Results</h3><p>We identified 10 studies. Two studies reported VE of primary immunisation with MenC vaccines ranging between 90% (74.9 – 96.1) and 84.1% (41.5 – 95.7) for periods of 2 and 7 years, respectively. Eight studies reported immunogenicity of primary immunisation with MenC and/or MenACWY vaccines, of which two reported -in addition- on booster immunisation. The percentage of participants with protective rSBA titers was high after primary immunisation but waned over the following 6 years. A single booster at the age of 7 years or older seems to prolong protection for several years.</p></div><div><h3>Conclusions</h3><p>A single dose of MenC or MenACWY vaccine at 12–23 months of age provides robust protection against MenC IMD. Data on booster immunisation are sparse, but indicate prolonged protection for three years at least.</p></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":null,"pages":null},"PeriodicalIF":14.3,"publicationDate":"2024-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0163445324001622/pdfft?md5=27e9a884043104cd3252df4e1aa72868&pid=1-s2.0-S0163445324001622-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141602067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of a complex second-generation HIV-1 circulating recombinant form (CRF158_0107) among men who have sex with men in China","authors":"","doi":"10.1016/j.jinf.2024.106230","DOIUrl":"10.1016/j.jinf.2024.106230","url":null,"abstract":"","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":null,"pages":null},"PeriodicalIF":14.3,"publicationDate":"2024-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0163445324001646/pdfft?md5=4e0d803ace4a708572bba6258bf31d2a&pid=1-s2.0-S0163445324001646-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141591935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vaccine effectiveness and impact of meningococcal vaccines against gonococcal infections: A systematic review and meta-analysis","authors":"Bing Wang PhD ,&nbsp;Hassen Mohammed PhD ,&nbsp;Prabha Andraweera PhD ,&nbsp;Mark McMillan PhD ,&nbsp;Helen Marshall MD","doi":"10.1016/j.jinf.2024.106225","DOIUrl":"10.1016/j.jinf.2024.106225","url":null,"abstract":"<div><h3>Objectives</h3><p>To systematically review and synthesis the evidence of vaccine effectiveness (VE) and impact (VI) of meningococcal vaccines in preventing gonorrhoea.</p></div><div><h3>Methods</h3><p>We systematically evaluated studies. Literature searches were conducted in PubMed, Embase, Cochrane Library, CINAHL, Google Scholar, clinical trial registries, and major health and immunisation conferences. Meta-analysis was performed with the DerSimonian-Laird random-effects model to estimate the pooled VE.</p></div><div><h3>Results</h3><p>Twelve studies met the criteria for inclusion. VE of meningococcal B (MenB) outer membrane vesicle (OMV) vaccines was evaluated in nine studies, with one study evaluating a non-OMV vaccine, MenB-FHbp. The majority of studies targeted individuals aged 15-30 years. Adjusted VE for OMV vaccines against gonorrhoea ranged from 22% to 46%. MenB-FHbp did not show protection against gonorrhoea. The pooled VE estimates of OMV vaccines against any gonorrhoea infection following the full vaccine series were 33-34%. VI was assessed for 4CMenB in Canada and Australia, for VA-MENGOC-BC in Cuba; and for MenBvac in Norway. VI ranged from a 30%-59% reduction in gonorrhoea incidence.</p></div><div><h3>Conclusions</h3><p>4CMenB and other MenB-OMV vaccines show moderate effectiveness against gonorrhoea. Further research is required to explore the factors associated with vaccine protection, informing more effective vaccination strategies for the management of gonococcal infections.</p></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":null,"pages":null},"PeriodicalIF":14.3,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0163445324001592/pdfft?md5=cce8978b62991cf481dcddb93bd31974&pid=1-s2.0-S0163445324001592-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141581419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Conflict and catastrophe-related severe burn injuries: A challenging setting for antimicrobial decision-making","authors":"Scott JC Pallett ,&nbsp;Rakhee Mistry ,&nbsp;Zoe L Lambert ,&nbsp;Stephen D Woolley ,&nbsp;Aula Abbara ,&nbsp;Aodhan O Breathnach ,&nbsp;Lucy E Lamb ,&nbsp;Andrew Williams ,&nbsp;Nabeela Mughal ,&nbsp;Olena Moshynets ,&nbsp;Stephen J Hughes ,&nbsp;Matthew K O’Shea ,&nbsp;Luke SP Moore","doi":"10.1016/j.jinf.2024.106224","DOIUrl":"10.1016/j.jinf.2024.106224","url":null,"abstract":"<div><p>Severe burns are a major component of conflict-related injuries and can result in high rates of mortality. Conflict and disaster-related severe burn injuries present unique challenges in logistic, diagnostic and treatment options, while wider conflict is associated with driving local antimicrobial resistance. We present a targeted review of available literature over the last 10 years on the use of systemic antimicrobial antibiotics in this setting and, given limited available data, provide an expert consensus discussion. While international guidelines do not tend to recommend routine use of prophylactic systemic antibiotics, the challenges of conflict settings and potential for polytrauma are likely to have ongoing impacts on antimicrobial decision-making and use. Efforts must be made to develop a suitable evidence base in this unique setting. In the interim, a pragmatic approach to balancing selective pressures of antimicrobial use with realistic access is possible.</p></div>","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":null,"pages":null},"PeriodicalIF":14.3,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0163445324001580/pdfft?md5=733b94356ab25d13747190c75850bd8c&pid=1-s2.0-S0163445324001580-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141581416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk for latent tuberculosis infection reactivation among patients with psoriasis on biologics treatment: A meta-analysis","authors":"Xinyu Zhu,&nbsp;Xiaoyuan Pan,&nbsp;Meihong Da,&nbsp;Fei Wang,&nbsp;Zhengbang Dong","doi":"10.1016/j.jinf.2024.106226","DOIUrl":"10.1016/j.jinf.2024.106226","url":null,"abstract":"","PeriodicalId":50180,"journal":{"name":"Journal of Infection","volume":null,"pages":null},"PeriodicalIF":14.3,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0163445324001609/pdfft?md5=d261253113173e1a3286b16ee79e246a&pid=1-s2.0-S0163445324001609-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141581418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}